NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$219.00
BRaf Polyclonal Antibody
Cat. #: 21271 |
Gene Symbol: B-RAF, B-RAF1, RAFB1 |
Description: Anti-BRaf Rabbit Polyclonal Antibody |
Background: B-Raf is a member of the Raf family of Ser/Thr protein kinases. It functions downstream of Ras to regulate the MAP kinase signaling pathway. Mutations in the B-RAF gene cause diseases. Inherited mutations in B-RAF cause cardiofaciocutaneous syndrome. Acquired mutations in B-RAF have been found in cancers. |
Immunogen: Purified B-Raf protein, human origin. |
Applications: ELISA, WB, IHC |
Recommended Dilutions: ELISA: 1:1000-1:5000 WB: 1:100-1:1000 IHC: 1:50-1:200 |
Concentration: 0.1mg/ml |
Host Species: Rabbit |
Format: Liquid |
Clonality: Polyclonal |
Isotype: |
Purity: Purified from serum |
Preservative: No |
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol |
Species Reactivity: Recognizes B-Raf of vertebrates. |
Storage Conditions: Store at -20°C. Avoid repeated freezing and thawing |
Immunohistochemistry:
Immunohistochemical analysis of paraffin-embedded human thyroid cancer tissue with anti- B-Raf polyclonal antibody (Cat. #21271). Tissue samples were fixed with formaldehyde and blocked with 1% serum for 15 min at 37 °C. Antigen retrieval was by heat mediation in citrate buffer (pH6). Samples were then incubated with primary antibody (1:50 dilution) overnight at 4°C. A HRP-conjugated Goat anti-mouse IgG (1:50 dilution) was used as secondary antibody.
1. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma Mod Pathol. 2013 Mar;26(3):414-20. |
2. Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients Tumor Biology. June 2014, Volume 35, Issue 6, pp 5727-5733 |
3. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma human pathology. February 2015Volume 46, Issue 2, Pages 169–175 |
4. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas human pathology. November 2013Volume 44, Issue 11, Pages 2563–2570 |
5. BRAF V600E Mutation-Specific Antibody: A Review Seminars in Diagnostic Pathology |